Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Halozyme Therapeutics (NASDAQ:HALO) had its target price upped by research analysts at Citizens Jmp from $93.00 to $149.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp‘s target price would indicate a potential upside of 43.78% from the stock’s current price.

A number of other research analysts have also recently weighed in on HALO. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Finally, Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.09.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $103.63 on Friday. The business’s fifty day moving average price is $115.19 and its 200 day moving average price is $84.73. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $134.00. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $11.76 billion, a P/E ratio of 26.37, a PEG ratio of 0.39 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. The company had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a return on equity of 488.26% and a net margin of 26.93%. The firm’s revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.72 earnings per share. As a group, research analysts anticipate that Halozyme Therapeutics will post 8.32 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Matthew L. Posard sold 5,230 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director owned 53,609 shares of the company’s stock, valued at approximately $5,818,720.86. This represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $83,995,132. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Horizon Investment Services LLC bought a new stake in Halozyme Therapeutics during the second quarter valued at $2,254,000. WINTON GROUP Ltd raised its holdings in shares of Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock worth $4,723,000 after purchasing an additional 52,848 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $1,025,000. Great Lakes Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $2,821,000. Finally, Chase Investment Counsel Corp bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $2,035,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.